Antibiotic Treatment for Pyelonephritis
Oral fluoroquinolones are the first-line treatment for uncomplicated pyelonephritis in outpatients where local resistance rates are <10%, with options including ciprofloxacin 500-750 mg twice daily for 7 days or levofloxacin 750 mg once daily for 5 days. 1, 2
Initial Assessment and Antibiotic Selection
- Always obtain urine culture and susceptibility testing before initiating therapy to guide definitive treatment 1, 2
- Initial empiric therapy should be tailored based on local resistance patterns and subsequently adjusted according to culture results 1
- The most common causative organism is Escherichia coli (75-95%), followed by other Enterobacteriaceae such as Proteus mirabilis and Klebsiella pneumoniae 1, 3
Outpatient Treatment Options
First-line options:
- Fluoroquinolones (in areas with <10% resistance):
When fluoroquinolone resistance exceeds 10%:
- Add an initial one-time IV dose of a long-acting parenteral antimicrobial (ceftriaxone 1g or an aminoglycoside) before starting oral therapy 1, 2
- Trimethoprim-Sulfamethoxazole (TMP-SMX) 160/800 mg twice daily for 14 days is appropriate only if the uropathogen is known to be susceptible 1, 2
Inpatient Treatment Options
- For patients requiring hospitalization, initial IV antimicrobial regimens include:
Treatment Duration
- Fluoroquinolones: 5-7 days depending on the specific agent 1, 2, 6
- TMP-SMX: 14 days 1, 2
- β-lactams (including cephalosporins): 10-14 days 1, 2
Special Considerations
Elderly patients:
- Monitor closely for adverse effects, particularly with aminoglycosides and fluoroquinolones 1
- Dose adjustment may be required for moderate renal impairment 2
Oral β-lactams:
- Less effective than fluoroquinolones for treating pyelonephritis 2
- If used, should be preceded by an initial IV dose of a long-acting parenteral antimicrobial (e.g., ceftriaxone 1g) 2
- Treatment duration of 10-14 days 1, 2
Common Pitfalls to Avoid
- Failing to obtain urine cultures before initiating antibiotics 1, 2
- Not considering local resistance patterns when selecting empiric therapy 1, 2, 6
- Using fluoroquinolones empirically in areas with >10% resistance without adding an initial dose of a parenteral agent 1, 2
- Using oral β-lactams as monotherapy without an initial parenteral dose 1, 2
- Not adjusting therapy based on culture results 1, 2
- Inadequate treatment duration, especially with β-lactam agents 1
- Using agents like nitrofurantoin or oral fosfomycin, which are not recommended for pyelonephritis due to insufficient efficacy data 2